Oragenics, which describes itself as “a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders” has announced the resignation of CEO Kimberly Murphy as part of “a mutually agreeable Separation Agreement.” The company specified that Murphy’s resignation “was not due to any disagreement with the Company on any matter related to its operations, policies or practices.” According to the announcement, Oragenics President Michael Redmond has been named Interim Principal Executive Officer, and the board will “provide direction to the Company during this transition in management.”
In October 2023, Oragenics announced a $1 million deal to acquire dry powder formulations and breath-powered nasal delivery technology from Odyssey Health, which had acquired one of the formulations from Prevacus. Funding for development of OPN-002 (formerly PRV-002) for the treatment of concussion, was at the center of a $2 million welfare fraud case involving Prevacus. Oragenics recently said that it is preparing for a Phase 2 trial of ONP-002.
Oragenics Executive Chairman of the Board Charles Pope commented, “We appreciate Ms. Murphy’s strategic leadership on the shift in the company’s focus to its recently acquired neurology assets and look forward to her continued positive impact on and support of the company as a director.”
Read the Oragenics press release.
